Darshana Manji Dadhania
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Darshana Manji Dadhania has a total of 617 co-authors. Here are the top co-authors by number of shared publications:
- John Richard Lee
Weill Cornell Medicine
15 shared publications - Manikkam Suthanthiran
Division of Nephrology and Hypertension, Department of Medicine, NewYork-Presbyterian-Weill Cornell Medicine, New York, NY, USA
12 shared publications - Thangamani Muthukumar
Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College
11 shared publications Manikkam Suthanthiran
Division of Nephrology and Hypertension, Department of Medicine, New York-Presbyterian Hospital–Weill Cornell Medical Center, New York, USA
10 shared publications- Iwijn De Vlaminck
Cornell University
9 shared publications - Michelle Lubetzky
Division of Nephrology, Weill Cornell Medicine , New York, NY, USA
9 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70323
Serial Blood Microbiome Profiles in Kidney Transplant Recipients Reveal Evidence of Circulating Gut and Non‐Gut Derived Microbial DNA
Background: In this study, we sought to investigate the utility of 16S rRNA gene sequencing of whole blood in kidney transplant recipients and to assess a link between the gut microbiota and the blood microbiota. Methods: We recruited 63 kidney transplant recipients who provided 163 whole blood specimens over the first 140 days after transplantation. We profiled the blood microbiome using 16S rRNA gene sequencing of the V4‐V5 hypervariable region. We additionally evaluated the gut microbiota via metagenomic sequencing in a subset of kidney transplant recipients who had matched blood specimens. Results: We generated a median of 19 959 sequences per blood specimen. We discovered that most whole blood microbiome profiles consisted of mitochondrial DNA (mean relative blood abundance greater than 99%) with minimal microbial DNA detected. Out of the 163 blood specimens, 83 (51%) had detectable microbial 16S rRNA sequences and there were 92 distinct taxa detected at the genus level. Among the 51 kidney transplant recipients, blood microbial 16S sequences were persistently detected in 10 kidney transplant recipients over time, intermittently detected in 29 kidney transplant recipients over time, and not detected in 12 kidney transplant recipients over time. Among 76 matched blood–fecal specimens, 9 blood specimens had detectable gut microbial 16S sequences, which were also detected in 3 of the 9 fecal specimens. Conclusion: Our study finds minimal detection of bacterial DNA in the blood microbiome in kidney transplant recipients and evidence of gut bacterial DNA in the bloodstream of kidney transplant recipients. image
- 21 September 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70323
Open AccessSerial Blood Microbiome Profiles in Kidney Transplant Recipients Reveal Evidence of Circulating Gut and Non‐Gut Derived Microbial DNA
Background: In this study, we sought to investigate the utility of 16S rRNA gene sequencing of whole blood in kidney transplant recipients and to assess a link between the gut microbiota and the blood microbiota. Methods: We recruited 63 kidney transplant recipients who provided 163 whole blood specimens over the first 140 days after transplantation. We profiled the blood microbiome using 16S rRNA gene sequencing of the V4‐V5 hypervariable region. We additionally evaluated the gut microbiota via metagenomic sequencing in a subset of kidney transplant recipients who had matched blood specimens. Results: We generated a median of 19 959 sequences per blood specimen. We discovered that most whole blood microbiome profiles consisted of mitochondrial DNA (mean relative blood abundance greater than 99%) with minimal microbial DNA detected. Out of the 163 blood specimens, 83 (51%) had detectable microbial 16S rRNA sequences and there were 92 distinct taxa detected at the genus level. Among the 51 kidney transplant recipients, blood microbial 16S sequences were persistently detected in 10 kidney transplant recipients over time, intermittently detected in 29 kidney transplant recipients over time, and not detected in 12 kidney transplant recipients over time. Among 76 matched blood–fecal specimens, 9 blood specimens had detectable gut microbial 16S sequences, which were also detected in 3 of the 9 fecal specimens. Conclusion: Our study finds minimal detection of bacterial DNA in the blood microbiome in kidney transplant recipients and evidence of gut bacterial DNA in the bloodstream of kidney transplant recipients. image
- Open Access
First Order Associations Between Banff Acute Lesions in Kidney Allograft Biopsies and a Urinary Cell Three-Gene Diagnostic Signature
Banff acute lesion scores underpin histologic classification of kidney allograft biopsies; however, biomarker studies rely on second-order associations with diagnostic categories that introduce confounding. We quantified the first order relationships between Banff acute lesion scores and the validated urinary cell three gene rejection signature. In 354 biopsy- urine pairs, three-gene signature scores computed using a locked regression equation incorporating absolute copy numbers of CD3E mRNA, CXCL10 mRNA, and 18S rRNA in urinary cell RNA-were related to glomerulitis (g), peritubular capillaritis (ptc), interstitial inflammation (i), and tubulitis (t). Signature scores rose monotonically with Banff acute lesion severity, with 1.5 to 1.8-fold higher odds of more severed g, ptc, i, and t (all P<0.0001), and showed good calibration. Associations remained robust for composite microvascular (g+ptc) and tubulointerstitial (i+t) indices and were strongest for severe g and t, supporting this signature as a noninvasive, quantitative readout of acute rejection pathology with immediate diagnostic applicability.
Open AccessFirst Order Associations Between Banff Acute Lesions in Kidney Allograft Biopsies and a Urinary Cell Three-Gene Diagnostic Signature
Banff acute lesion scores underpin histologic classification of kidney allograft biopsies; however, biomarker studies rely on second-order associations with diagnostic categories that introduce confounding. We quantified the first order relationships between Banff acute lesion scores and the validated urinary cell three gene rejection signature. In 354 biopsy- urine pairs, three-gene signature scores computed using a locked regression equation incorporating absolute copy numbers of CD3E mRNA, CXCL10 mRNA, and 18S rRNA in urinary cell RNA-were related to glomerulitis (g), peritubular capillaritis (ptc), interstitial inflammation (i), and tubulitis (t). Signature scores rose monotonically with Banff acute lesion severity, with 1.5 to 1.8-fold higher odds of more severed g, ptc, i, and t (all P<0.0001), and showed good calibration. Associations remained robust for composite microvascular (g+ptc) and tubulointerstitial (i+t) indices and were strongest for severe g and t, supporting this signature as a noninvasive, quantitative readout of acute rejection pathology with immediate diagnostic applicability.
- 21 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Summary recommendations from the National Cancer Institute Clinical Trials Planning Meeting on advanced cutaneous squamous cell carcinoma in immunosuppressed patients
Immunosuppression is a major, known risk factor for cutaneous squamous cell carcinoma. Immunosuppressed patients with cutaneous squamous cell carcinoma are at significantly increased risk of recurrence and death compared with their nonimmunosuppressed counterparts. To date, this high-risk population has been excluded from most clinical trials. The National Cancer Institute (NCI) Head and Neck Cancer Steering Committee commissioned a Clinical Trials Planning Meeting (CTPM) specifically for immunosuppressed patients with high-risk or advanced cutaneous squamous cell carcinoma. The CTPM was designed to bring together key scientific and pharmaceutical stakeholders, as well as multidisciplinary physician subspecialists who manage these high-risk, complex patients, with the goal of developing clinical trial concepts that could be readily conducted through the NCI Clinical Trial Network (NCTN) groups. With extensive virtual preplanning and a 2-day in-person summary meeting, the CTPM was structured as 2 multidisciplinary breakout groups focused on immunosuppressed populations with either (1) high-risk resectable cutaneous squamous cell carcinoma or (2) advanced unresectable and or metastatic cutaneous squamous cell carcinoma. Five clinical trial concepts were designed specifically for immunosuppressed patients and suitable to conduct via NCI Clinical Trial Network groups. A CTPM was successfully conducted for immunosuppressed patients with cutaneous squamous cell carcinoma, a historically underserved population with poor clinical outcomes.
- 21 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Summary recommendations from the National Cancer Institute Clinical Trials Planning Meeting on advanced cutaneous squamous cell carcinoma in immunosuppressed patients
Immunosuppression is a major, known risk factor for cutaneous squamous cell carcinoma. Immunosuppressed patients with cutaneous squamous cell carcinoma are at significantly increased risk of recurrence and death compared with their nonimmunosuppressed counterparts. To date, this high-risk population has been excluded from most clinical trials. The National Cancer Institute (NCI) Head and Neck Cancer Steering Committee commissioned a Clinical Trials Planning Meeting (CTPM) specifically for immunosuppressed patients with high-risk or advanced cutaneous squamous cell carcinoma. The CTPM was designed to bring together key scientific and pharmaceutical stakeholders, as well as multidisciplinary physician subspecialists who manage these high-risk, complex patients, with the goal of developing clinical trial concepts that could be readily conducted through the NCI Clinical Trial Network (NCTN) groups. With extensive virtual preplanning and a 2-day in-person summary meeting, the CTPM was structured as 2 multidisciplinary breakout groups focused on immunosuppressed populations with either (1) high-risk resectable cutaneous squamous cell carcinoma or (2) advanced unresectable and or metastatic cutaneous squamous cell carcinoma. Five clinical trial concepts were designed specifically for immunosuppressed patients and suitable to conduct via NCI Clinical Trial Network groups. A CTPM was successfully conducted for immunosuppressed patients with cutaneous squamous cell carcinoma, a historically underserved population with poor clinical outcomes.
- 14 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2484-2496
Urinary single-cell transcriptomics in kidney transplantation: Elucidation of donor-recipient cellular dynamics and fibrogenic stress
- 14 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2484-2496
Urinary single-cell transcriptomics in kidney transplantation: Elucidation of donor-recipient cellular dynamics and fibrogenic stress
- Open Access
- 7 May 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (6) , e1934
Practical Guide to Address Common Myths in the Pre– and Post–kidney Transplant Management of the Elderly Patient with Cancer: An Opinion Paper
Two areas of overlap between kidney transplantation and oncology that remain fraught with uncertainty and bias are (1) transplant candidacy for elderly patients with historic or active cancers or premalignant conditions, and (2) managing cancer in elderly kidney transplant recipients. These have led to inadvertent inequities in the care of elderly kidney transplant candidates with historic or active malignancies. Incorporating a patient’s viewpoint and an oncologist’s perspective, we present a nuanced, multidisciplinary approach to management that goes beyond mere consideration of chronological age and focuses on the individual patient and his/her goals.
- 7 May 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (6) , e1934
Open AccessPractical Guide to Address Common Myths in the Pre– and Post–kidney Transplant Management of the Elderly Patient with Cancer: An Opinion Paper
Two areas of overlap between kidney transplantation and oncology that remain fraught with uncertainty and bias are (1) transplant candidacy for elderly patients with historic or active cancers or premalignant conditions, and (2) managing cancer in elderly kidney transplant recipients. These have led to inadvertent inequities in the care of elderly kidney transplant candidates with historic or active malignancies. Incorporating a patient’s viewpoint and an oncologist’s perspective, we present a nuanced, multidisciplinary approach to management that goes beyond mere consideration of chronological age and focuses on the individual patient and his/her goals.
- Open Access
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Benchmarking urinary cell transcriptomes for noninvasive differentiation of BK polyomavirus–associated nephropathy from T cell–mediated rejection
BK polyomavirus–associated nephropathy (BKVN) adversely impacts kidney allograft survival and often mimics acute T cell–mediated rejection (TCMR), confounding diagnosis and management. To address this conundrum, we performed unbiased RNA sequencing of urinary cells matched to biopsies classified as BKVN with intragraft inflammation (BKVN-P), BKVN without inflammation (BKVN-N), TCMR, or no rejection (NR). BKVN-N displayed dominant host DNA replication, cell cycle, and repair programs, while BKVN-P samples exhibited expansive innate immune activation, antigen presentation, chemokine upregulation, and epithelial injury. Both BKVN subtypes shared signatures of T cell exhaustion and mature and tolerogenic dendritic cell activation but differed in immune orientation — Th1 predominance in BKVN-N versus Treg and CD8 enrichment in BKVN-P. Compared with TCMR samples, BKVN-P lacked robust TCR/CD28 signaling and was enriched for viral and innate modules; BKVN-N lacked alloimmune activation. B cell exhaustion characterized BKVN-N, while BKVN-P displayed robust B cell activation with metabolic downregulation. A ratiometric urinary cell biomarker, CXCL10 mRNA/CD3E mRNA, distinguished both BKVN subtypes from TCMR with diagnostic accuracy, replicated by quantitative reverse transcription PCR for clinical translation, and confirmed in an independent cohort. These findings demonstrate the utility of urinary cell transcriptomics for resolving viral injury from alloimmunity, enabling precision diagnostics and targeted immunomodulation in kidney transplantation.
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Open AccessBenchmarking urinary cell transcriptomes for noninvasive differentiation of BK polyomavirus–associated nephropathy from T cell–mediated rejection
BK polyomavirus–associated nephropathy (BKVN) adversely impacts kidney allograft survival and often mimics acute T cell–mediated rejection (TCMR), confounding diagnosis and management. To address this conundrum, we performed unbiased RNA sequencing of urinary cells matched to biopsies classified as BKVN with intragraft inflammation (BKVN-P), BKVN without inflammation (BKVN-N), TCMR, or no rejection (NR). BKVN-N displayed dominant host DNA replication, cell cycle, and repair programs, while BKVN-P samples exhibited expansive innate immune activation, antigen presentation, chemokine upregulation, and epithelial injury. Both BKVN subtypes shared signatures of T cell exhaustion and mature and tolerogenic dendritic cell activation but differed in immune orientation — Th1 predominance in BKVN-N versus Treg and CD8 enrichment in BKVN-P. Compared with TCMR samples, BKVN-P lacked robust TCR/CD28 signaling and was enriched for viral and innate modules; BKVN-N lacked alloimmune activation. B cell exhaustion characterized BKVN-N, while BKVN-P displayed robust B cell activation with metabolic downregulation. A ratiometric urinary cell biomarker, CXCL10 mRNA/CD3E mRNA, distinguished both BKVN subtypes from TCMR with diagnostic accuracy, replicated by quantitative reverse transcription PCR for clinical translation, and confirmed in an independent cohort. These findings demonstrate the utility of urinary cell transcriptomics for resolving viral injury from alloimmunity, enabling precision diagnostics and targeted immunomodulation in kidney transplantation.
- 22 April 2026
- Published by Elsevier in Transplantation Reviews
- Vol. 40 (4) , 101022
Center-based obstacles and facilitators in the utilization of kidney paired donation in the United States, 2008–2023: A scoping review
- 22 April 2026
- Published by Elsevier in Transplantation Reviews
- Vol. 40 (4) , 101022
Center-based obstacles and facilitators in the utilization of kidney paired donation in the United States, 2008–2023: A scoping review
- 6 April 2026
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
Kidney-paired donation: benefits and challenges
Purpose of review: Living-donor kidney transplantation offers the highest survival benefit for patients with kidney failure, yet access remains limited by immunologic, biologic, geographic and logistical barriers. This review summarized recent developments in kidney-paired donation (KPD), highlights current challenges and outlines future directions to optimize program performance and equity. Recent findings: KPD has expanded rapidly in the Unites States and globally, with multicenter national and transnational programs demonstrating excellent allograft and patient outcomes. Increasing the use of altruistic donors, advanced donation models and molecular HLA-matching algorithms have improved match rates and compatibility. Despite these advances, significant challenges persist, including overrepresentation of Blood Group O and highly sensitized candidates, uneven program participation, financial and logistical barriers, and the need for robust ethical frameworks. Summary: Creating a national KPD program that is accessible to all transplant programs and incorporates compatible recipient–donor pairs would significantly improve the opportunities for living-donor kidney transplantation.
- 6 April 2026
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
Kidney-paired donation: benefits and challenges
Purpose of review: Living-donor kidney transplantation offers the highest survival benefit for patients with kidney failure, yet access remains limited by immunologic, biologic, geographic and logistical barriers. This review summarized recent developments in kidney-paired donation (KPD), highlights current challenges and outlines future directions to optimize program performance and equity. Recent findings: KPD has expanded rapidly in the Unites States and globally, with multicenter national and transnational programs demonstrating excellent allograft and patient outcomes. Increasing the use of altruistic donors, advanced donation models and molecular HLA-matching algorithms have improved match rates and compatibility. Despite these advances, significant challenges persist, including overrepresentation of Blood Group O and highly sensitized candidates, uneven program participation, financial and logistical barriers, and the need for robust ethical frameworks. Summary: Creating a national KPD program that is accessible to all transplant programs and incorporates compatible recipient–donor pairs would significantly improve the opportunities for living-donor kidney transplantation.
- Top Cited PapersOpen Access
- 5 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 922-936
The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning
- 5 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 922-936
Top Cited PapersOpen AccessThe Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning
- Open Access
Impact of COVID-19 vaccination on long-Term patient and kidney allograft survival following SARS-CoV-2 infection
The long-term impact of SARS-CoV-2 infection on kidney allograft survival remains incompletely understood, particularly regarding the influence of vaccination, acute kidney injury (AKI), and post-infection immunosuppression. We conducted a retrospective analysis of 129 kidney transplant recipients with confirmed SARS-CoV-2 infection between March 2020 and March 2022 with a median follow-up of 50 months. Among 129 recipients, 106 (82%) received vaccination at any time before or after SARS-CoV-2 infection (82%) while 23 (18%) remained unvaccinated. Unvaccinated patients experienced significantly lower long-term graft survival (52% vs. 85%; p = 0.0004) and patient survival (83% vs. 99%; p = 0.0003) compared with vaccinated recipients. AKI occurred in 15% of recipients and independently predicted graft failure (aHR 2.88; p = 0.0341). Post–SARS-CoV-2 serum creatinine and albuminuria were strong prognostic markers of graft loss. Unvaccinated status independently predicted graft failure in both transplantation-anchored (aHR 2.80; p = 0.0342) and SARS-CoV-2–anchored models (aHR 5.31; p = 0.0004). Continuation of mycophenolate mofetil at post-infection assessment was associated with reduced graft-failure risk (aHR 0.99; p = 0.0193). These findings underscore the importance of sustained vaccination in preserving long-term allograft function.
Open AccessImpact of COVID-19 vaccination on long-Term patient and kidney allograft survival following SARS-CoV-2 infection
The long-term impact of SARS-CoV-2 infection on kidney allograft survival remains incompletely understood, particularly regarding the influence of vaccination, acute kidney injury (AKI), and post-infection immunosuppression. We conducted a retrospective analysis of 129 kidney transplant recipients with confirmed SARS-CoV-2 infection between March 2020 and March 2022 with a median follow-up of 50 months. Among 129 recipients, 106 (82%) received vaccination at any time before or after SARS-CoV-2 infection (82%) while 23 (18%) remained unvaccinated. Unvaccinated patients experienced significantly lower long-term graft survival (52% vs. 85%; p = 0.0004) and patient survival (83% vs. 99%; p = 0.0003) compared with vaccinated recipients. AKI occurred in 15% of recipients and independently predicted graft failure (aHR 2.88; p = 0.0341). Post–SARS-CoV-2 serum creatinine and albuminuria were strong prognostic markers of graft loss. Unvaccinated status independently predicted graft failure in both transplantation-anchored (aHR 2.80; p = 0.0342) and SARS-CoV-2–anchored models (aHR 5.31; p = 0.0004). Continuation of mycophenolate mofetil at post-infection assessment was associated with reduced graft-failure risk (aHR 0.99; p = 0.0193). These findings underscore the importance of sustained vaccination in preserving long-term allograft function.